We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS and Pfizer Prevail in Challenge Over Eliquis Patents
BMS and Pfizer Prevail in Challenge Over Eliquis Patents
Bristol Myers Squibb and collaborator Pfizer prevailed in a patent ruling last week when a Delaware federal judge upheld two patents for their blockbuster blood thinner Eliquis (apixaban).